[Metabolic syndrome in men of 35-65 years old from rural district of Poltava region and possibility of the prophylactic therapy with atorvastatine].
Observation of 250 men aged 35-65 years (middle age was 52 +/- 2 years) showed that prevalence of MS was 27%. Atorvastatine administration at dose of 10-20 mg per day for patients with ischemic heart disease and chronic obstructive lung disease associated with MS reduced during month administration the level of cholesterol, triglycerides, beta- and pre-beta-lipoproteids and increased the level of alpha-cholesterol in blood of these patients. Addition of atorvastatine to a common treatment patients with chronic obstructive lung disease improved as well the clinical picture of systemic inflammation process.
Kaĭdashev
I P
IP
Vasil'ev
V N
VN
Gorbas'
I M
IM
Petrushov
A V
AV
Rasin
M S
MS
Rasin
A M
AM
Smirnova
I P
IP
Iakimishina
L I
LI
D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000069059:Atorvastatin; D001835:Body Weight; D002318:Cardiovascular Diseases / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control*; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D008055:Lipids / Q000097:blood*; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology; D008875:Middle Aged; D011758:Pyrroles / Q000008:administration & dosage / Q000627:therapeutic use*; D012423:Rural Health; D012424:Rural Population; D014455:Ukraine / Q000453:epidemiology
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D008055:Lipids; D011758:Pyrroles; D000069059:Atorvastatin